Apellis Pharmaceuticals Inc
NEWS
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund’s original target was just at $350 million.
May is a busy month for the U.S. Food and Drug Administration (FDA)’s calendar for new drug reviews. Here’s a look.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
Apellis Pharmaceuticals terminated its investigational COVID-19 asset after study data showed the therapeutic failed to reduce mortality rate in patients compared to standard of care.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
JOBS
IN THE PRESS